
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc. is focused on the treatment of primary and metastatic liver cancers through its innovative product, Melphalan Hydrochloride for Injection with the Delcath Hepatic Delivery System, which allows for high-dose chemotherapy specifically targeting the liver. The company's management is effectively expanding its treatment centers, anticipating positive results from the CHOPIN trial and the Medicaid National Drug Rebate Agreement (NDRA) program, contributing to the projected revenue growth despite lower overall forecasts, alongside improving margins that support profitability. Additionally, the expected adoption of Hepzato is bolstered by positive clinical data, a strategic increase in site activations, and initiatives aimed at enhancing referrals and reach into new geographic regions by 2025, fostering a strong outlook for continued growth through 2026.
Bears say
Delcath Systems Inc. reported a decline in preliminary total revenues for 3Q25, reaching $20.5 million, which represents a 15% quarter-over-quarter drop from $24.2 million in 2Q25 and falls below consensus estimates of $23.8 million. The company has revised its full-year revenue guidance for FY2025 down to $83 million to $85 million from a previous range of $93 million to $96 million, reflecting challenges such as decreased new site activations, reduced patient starts, and a decline in revenue per kit due to the Medicaid National Drug Rebate Agreement Program. Additionally, projected revenue for 2026 has been lowered significantly from $153.2 million to $107.6 million, indicating increasing uncertainty and unfavorable market conditions impacting Delcath's growth trajectory.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares